ALX ONCOLOGY HOLDINGS INC (ALXO)

Insider Trading Filed: 2026-04-17

Key Insights

• The reporting person, Jeff E. Knight, who is the Chief Development and Operating Officer of ALX Oncology Holdings Inc., has acquired 800,000 stock options to purchase the company's common stock at an exercise price of $1.68 per share.
• The stock options vest over 4 years, with 1/4th of the shares vesting on April 13, 2027 and the remaining shares vesting monthly thereafter.
• This significant acquisition of stock options by a key executive suggests the reporting person's confidence in the company's future and their alignment with shareholder interests.

Sentiment: Positive Significance: 7/10

View Original Filing →

Insider Trading Filed: 2026-04-17

Key Insights

• The reporting person, Barbara Klencke, acquired 100,000 stock options of ALX Oncology Holdings Inc. (ALXO) on April 16, 2026, with a strike price of $1.68 and a 10-year expiration date.
• The options vest over a 4-year period, with 1/4th vesting on February 25, 2027 and the remaining vesting monthly thereafter.
• This insider purchase suggests that the Chief Medical Officer is bullish on the company's prospects and believes the stock is currently undervalued.

Sentiment: Positive Significance: 7/10

View Original Filing →

Current Report Filed: 2026-04-13

Key Insights

• ALX Oncology Holdings Inc. has appointed Jeff Knight as its new Chief Development and Operating Officer, bringing extensive experience in portfolio management, strategy, and operations from his previous roles at Crinetics Pharmaceuticals, Poseida Therapeutics, and other leading biopharmaceutical companies.
• The employment offer letter provides Mr. Knight with a competitive compensation package, including an annual base salary of $565,000, a target cash bonus of 40% of his base salary, and a stock option grant of 800,000 shares vesting over four years.
• The appointment of an experienced and seasoned executive like Jeff Knight to a key leadership role could signal the company's commitment to advancing its drug development pipeline and operational execution as it seeks to drive long-term growth and shareholder value.

Sentiment: Positive Significance: 7/10

View Original Filing →

Insider Trading Filed: 2026-03-23

Key Insights

• Insider Jason Lettmann, the CEO of ALX Oncology Holdings, sold 12,311 shares of common stock on March 19, 2026 for $2.17 per share, likely to satisfy tax obligations from the vesting of performance-based restricted stock units.
• After the sale, Lettmann still holds a significant direct ownership stake of 293,609 shares, indicating his continued alignment with shareholders.
• The stock sale appears to be a routine transaction to cover tax liabilities and not a broader bearish signal, as Lettmann maintains a substantial equity position in the company.

Sentiment: Neutral Significance: 4/10

View Original Filing →

Insider Trading Filed: 2026-03-23

Key Insights

• The reporting person, Shelly Pinto, sold 903 shares of common stock in ALX Oncology Holdings Inc. (ALXO) on March 19, 2026 to satisfy tax obligations related to the vesting of performance-based restricted stock units.
• Following the reported transaction, the reporting person continues to hold a direct ownership of 86,805 shares of common stock in the company.
• The sale of shares by an insider, particularly to cover tax obligations, could be seen as a neutral signal as it does not necessarily indicate a broader change in the insider's view of the company's prospects.

Sentiment: Neutral Significance: 4/10

View Original Filing →

Annual Report Filed: 2026-03-09

Key Insights

• The company has entered into several collaboration agreements, including with Tallac Therapeutics and Selexis SA, which could expand its pipeline and revenue opportunities.
• ALX Oncology has been actively issuing shares through at-the-market offerings, which could provide additional capital to fund its operations and development efforts.
• The company has granted performance-based restricted stock units and stock options as part of its compensation programs, which could align employee incentives with shareholder value creation.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-02-20

Key Insights

• Shelly Pinto, the SVP of Finance and CAO, sold 565 shares of ALX Oncology Holdings Inc. (ALXO) on February 18, 2026 at $2.27 per share. This sale was likely to satisfy tax obligations related to the vesting of restricted stock units.
• Following the reported transaction, Pinto now beneficially owns 87,708 shares of ALXO, indicating she continues to hold a significant position in the company.
• Insider selling, even for tax purposes, can sometimes be viewed negatively by investors, as it may signal management's lack of confidence in the company's future performance.

Sentiment: Neutral Significance: 4/10

View Original Filing →

Insider Trading Filed: 2026-02-04

Key Insights

• Corey S. Goodman, a director and 10% owner of ALX Oncology Holdings Inc., acquired a significant number of 3,184,713 common shares at $1.57 per share, indicating strong confidence in the company's prospects.
• The filing also reveals Goodman's indirect beneficial ownership of additional 4,598,970 shares through various investment vehicles, suggesting he has a substantial stake in the company.
• The large insider purchase, representing a significant increase in Goodman's ownership position, could signal positive developments or growth opportunities at ALX Oncology that the director believes will drive shareholder value.

Sentiment: Positive Significance: 7/10

View Original Filing →

Current Report Filed: 2026-01-30

Key Insights

• The company is conducting a public offering to raise approximately $150 million in gross proceeds, which could provide additional capital to fund its operations and development activities.
• The offering includes the issuance of 76,979,112 shares of common stock and 18,574,120 pre-funded warrants, providing investors with flexibility in their investment approach.
• The pre-funded warrants have customized terms, including limitations on the percentage of ownership that can be acquired, which may be of interest to certain investors.

Sentiment: Positive Significance: 7/10

View Original Filing →

Current Report Filed: 2026-01-30

Key Insights

• The company announced positive data from a Phase 1b/2 clinical trial evaluating its investigational CD47-inhibitor evorpacept in combination with Jazz Pharmaceuticals' ZIIHERA® (zanidatamab-hrii) in heavily pretreated patients with metastatic breast cancer. The topline findings indicate that CD47 expression is predictive of evorpacept activity in patients with confirmed HER2-positive metastatic breast cancer.
• The company disclosed preliminary unaudited financial information, estimating that it had approximately $48.3 million of cash and cash equivalents and short-term and long-term investments as of December 31, 2025. However, this estimate is subject to change upon completion of the company's financial statement closing procedures.
• The company cautioned that the preliminary financial information has not been audited, does not present all necessary information for a complete understanding of the company's financial position, and is subject to change.

Sentiment: Positive Significance: 7/10

View Original Filing →

Insider Trading Filed: 2026-01-28

Key Insights

• Insider Harish Shantharam has been granted a stock option to acquire 303,000 shares of ALX Oncology common stock, vesting over 4 years. This indicates management's confidence in the company's long-term prospects.
• The exercise price of $1.48 per share suggests the option was granted at the current market price, aligning Harish's incentives with shareholders.
• As Chief Financial Officer, Harish's equity grant signals an important leadership change and potential strategic direction for the company.

Sentiment: Positive Significance: 7/10

View Original Filing →

Insider Trading Filed: 2026-01-28

Key Insights

• Shelly Pinto, the Senior Vice President of Finance and Chief Accounting Officer, was granted a stock option to purchase 192,000 shares of ALX Oncology Holdings Inc. (ALXO) common stock at an exercise price of $1.48 per share.
• The stock option vests in 48 equal monthly installments starting February 26, 2026, aligning Pinto's incentives with long-term shareholder value creation.
• Insider transactions, such as this stock option grant, can provide insights into management's confidence in the company's future prospects and their commitment to the business.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-01-28

Key Insights

• The CEO Jason Lettmann acquired 912,000 stock options at an exercise price of $1.48, indicating his confidence in the company's future performance.
• The options vest over a 4-year period, aligning Lettmann's incentives with long-term shareholder value creation.
• Insider buying of this magnitude is a positive signal, as it suggests the CEO believes the stock is undervalued and expects the company to perform well.

Sentiment: Positive Significance: 7/10

View Original Filing →

Current Report Filed: 2026-01-21

Key Insights

• ALX Oncology Holdings Inc. has amended its 2025 Inducement Equity Incentive Plan to increase the number of shares reserved for issuance under the plan by 1,300,000 shares.
• The amendment to the Inducement Plan was adopted by the Board of Directors without stockholder approval, as permitted by the Nasdaq Stock Market's inducement award exception.
• The Inducement Plan provides for the grant of equity-based awards to individuals who are not previously employees or non-employee directors of the company, as an inducement for them to join the company.

Sentiment: Positive Significance: 5/10

View Original Filing →

Insider Trading Filed: 2026-01-21

Key Insights

• Corey S. Goodman, a director and 10% owner of ALX Oncology Holdings Inc (ALXO), acquired 40,400 stock options with an exercise price of $1.32, vesting over 12 months starting February 2026.
• The insider acquisition of a sizable option position suggests Goodman's confidence in the company's future prospects and alignment with shareholder interests.
• The timing of the option grant, shortly before the reported transaction date, indicates potential strategic planning around equity incentives for key personnel.

Sentiment: Positive Significance: 7/10

View Original Filing →

Insider Trading Filed: 2026-01-21

Key Insights

• The reporting person, J. Scott Garland, acquired 40,400 stock options with an exercise price of $1.32 and a vesting period of 12 months, indicating potential insider confidence in the company's future performance.
• The option grant suggests the company may be incentivizing its directors to align their interests with those of shareholders through equity-based compensation.
• Insider transactions can provide insights into management's outlook on the company's prospects, though further analysis of the broader context would be needed to fully assess the significance.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-01-21

Key Insights

• The reporting person, Alan B. Sandler, a director of ALX Oncology Holdings Inc., has acquired 10,100 stock options with an exercise price of $1.32 and a vesting period of 12 months.
• This insider transaction suggests that Sandler has a positive outlook on the company's future and is willing to invest in its equity.
• The stock option grant represents a long-term commitment to the company, potentially aligning Sandler's interests with those of other shareholders.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-01-21

Key Insights

• Insider Daniel J. Curran, a director of ALX Oncology, acquired 16,833 stock options with an exercise price of $1.32, vesting over 12 months. This could signal his confidence in the company's future prospects.
• The stock option grant suggests the company is providing equity-based incentives to its directors to align their interests with those of shareholders.
• Investors should monitor Curran's future transactions and whether other insiders also participate in similar option grants, as it could indicate management's belief in the company's growth potential.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-01-21

Key Insights

• This Form 4 filing indicates that Chris H. Takimoto, a director of ALX Oncology Holdings Inc., has acquired 40,400 stock options with an exercise price of $1.32 and a vesting period of 12 months. This suggests the company is incentivizing its board members to align their interests with shareholders.
• The timing of this option grant, coming in January 2026, may indicate the company is entering a critical phase of development or commercialization, where strong leadership and strategic guidance from the board will be crucial.
• The relatively low exercise price of $1.32 compared to the current stock price could make these options attractive to the director, potentially signaling their confidence in the company's future performance.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-01-21

Key Insights

• Rekha Hemrajani, a director of ALX Oncology Holdings, acquired 40,400 stock options with an exercise price of $1.32 and a 10-year term, indicating their belief in the company's long-term prospects.
• The options vest in 12 equal monthly installments starting in February 2026, suggesting a commitment to the company and confidence in its future performance.
• This insider transaction could signal positive sentiment towards ALX Oncology's strategic direction and growth potential.

Sentiment: Positive Significance: 6/10

View Original Filing →